As of September 27, 2026, OpenEvidence has not filed a registration statement, and no Form S-1 appears on SEC EDGAR, which covers only US filings. Crunchbase News reported on September 2, 2026 that OpenEvidence was one of eight startups it judged to have a 'probable' chance of an IPO within six months, citing CEO Daniel Nadler's view that foundation-model companies such as OpenAI and Anthropic need to go public before application-layer companies like OpenEvidence can follow. On September 24, 2026, Business Insider reported that OpenEvidence had raised $250 million from hospital systems and Andreessen Horowitz at a $15 billion valuation, up from the $12 billion it reached in a January 2026 round. Separately, on September 22, 2026, Reuters reported that Anthropic and OpenEvidence had announced a partnership to expand AI-powered clinical decision support to physicians in dozens of low- and middle-income countries. None of this reporting is an IPO filing or a confirmed date. Track SEC EDGAR and OpenEvidence's own statements directly, not secondary chatter.
Segmara is an independent research site. Segmara does not sell, broker, or arrange share purchases. Nothing here is investment advice.
Key points
A 'probable' rating, not a filing
Crunchbase News reported on September 2, 2026 that OpenEvidence was one of eight startups it judged to have a 'probable' chance of going public within six months. The assessment was tied to comments from CEO Daniel Nadler, whom Crunchbase said believes foundation-model companies such as OpenAI and Anthropic have to complete their own public listings before application-layer companies like OpenEvidence follow onto the market.
That is an analyst's forward-looking read, not a registration statement. As of September 27, 2026, no Form S-1 or F-1 for OpenEvidence appears on SEC EDGAR, which covers only US filings, and OpenEvidence has not announced a listing date.
The valuation has moved fast
Business Insider reported on September 24, 2026 that OpenEvidence raised $250 million from hospital systems and Andreessen Horowitz at a valuation of $15 billion. That is up from the $12 billion valuation it reached in a January 2026 round, according to the same report.
Neither figure is tied to a public offering price; both describe private funding rounds.
A partnership with one of the foundation-model companies it's waiting on
On September 22, 2026, Reuters reported that Anthropic and OpenEvidence had announced a partnership to expand AI-powered clinical decision support to physicians in dozens of low- and middle-income countries.
The deal links OpenEvidence to Anthropic, one of the foundation-model companies that CEO Daniel Nadler said, per Crunchbase News, needs to go public before application-layer companies like OpenEvidence can follow. The partnership itself is a product and distribution deal, not an IPO step.
AI-ready data summary
A structured extraction layer for this article: catalogue numbers, price context, chart values, and route-specific facts that search and AI systems can read directly from the page.
Metric
Value
Context
Canonical route
/blog/when-will-openevidence-ipo
Stable URL path for AI and search extraction.
Article title
When Will OpenEvidence IPO? A $15 Billion Valuation, Still No Filing
Main page topic.
Attached public sources
3
Number of citation links rendered at the bottom of the article.
Segmara listed companies
51
Live private-company listings in the public catalogue.
Priced listings
37
Catalogue listings with visible indicative or direct marks.
Listings without an indicative price
14
Catalogue listings where a public price is intentionally not invented.
Data fingerprint chart
Visible pricing coverage72%
37 of 51 listings show a mark
Stage
Timing
Price / valuation signal
Interpretation
Chart metric
Score
Interpretation
Visible pricing coverage
72 / 100
37 of 51 listings show a mark
Analytical lens
Search intent
Searches like 'When Will OpenEvidence IPO? A $15 Billion Valuation, Still No Filing' are research questions: what a filing or a company statement confirms, what has only been reported, and what is still unknown.
What counts as a listing step
For an IPO, the primary record is a registration statement filed with the securities regulator of the listing market, such as an S-1 or F-1 on SEC EDGAR for a US listing. Funding rounds, valuations and secondary-market prices are context, not listing steps.
Segmara role
Segmara is an independent research site. It does not sell, broker, or arrange share purchases, and nothing on this page is investment advice.
How a company reaches a US listing
The SEC filing trail
DraftThe company can first submit a draft registration statement (DRS) for confidential SEC review.
S-1 or F-1The registration statement goes public on SEC EDGAR: Form S-1, or Form F-1 for many foreign companies. A company that used a draft must file publicly at least 15 days before its roadshow.
AmendmentsS-1/A or F-1/A amendments answer SEC comments, and one of them adds the expected price range.
PricingOnce the SEC declares the registration effective, the company sets the price with its underwriters and files the final prospectus, usually a 424B4.
First tradeThe shares start trading on the exchange named in the prospectus, such as Nasdaq or the NYSE.
OpenEvidence is not on Segmara Pro's EDGAR alert list, so no alert is posted for its filings. To look for one, search its name with EDGAR full-text search. Segmara Pro's weekly IPO brief, posted in the members forum, covers filings and pricing across the IPO calendar.
No Form S-1 or F-1 for OpenEvidence appears on SEC EDGAR as of September 27, 2026; Crunchbase News reported on September 2, 2026 that the company was among eight startups it rated a 'probable' candidate for an IPO within six months, citing CEO Daniel Nadler's view that foundation-model makers such as OpenAI and Anthropic must list first.
Business Insider reported on September 24, 2026 that OpenEvidence raised $250 million from hospital systems and Andreessen Horowitz, lifting its valuation to $15 billion from the $12 billion it reached in a January 2026 round.
Reuters reported on September 22, 2026 that Anthropic and OpenEvidence had partnered to expand AI-powered clinical decision support to physicians in dozens of low- and middle-income countries.
Risk notes
Rumor risk: unofficial dates, valuations, or funding details circulating on social media or forums are frequently wrong or outdated and should not be treated as confirmation of anything.
Illiquidity risk: any private-market interest, indicative marks, or pre-IPO share arrangements in a company that has not listed can be difficult to exit and may not reflect a tradable price.
Timing risk: a company can pause, restart, or abandon IPO preparation at any stage, including after a confidential or public filing, so no step before pricing guarantees a listing.
Free: every article, the IPO calendar and the weekly IPOs page. Segmara Pro posts a weekly IPO brief in the members forum. 7-day free trial, then $15 a month (plus any applicable tax). Research only, no share sales.
Can retail investors track private-company shares on Segmara?
Yes. The free pre-IPO tracker sends indicative marks by email, with no card and no documents. Segmara does not sell, broker, or arrange share purchases.
Why was this market historically hard for retail investors to reach?
Private-company share access has often moved through private equity firms, venture funds, insiders, institutions, and relationship-driven secondary networks. Segmara makes research simpler: anyone can follow named private companies for free, by email.
What is the easiest next step?
Open the free pre-IPO tracker first, email only. The IPO calendar is free, and Segmara Pro adds a weekly IPO brief.
Has OpenEvidence confirmed an IPO date?
No. As of September 27, 2026, no S-1 or F-1 has been filed on SEC EDGAR. Crunchbase News rated OpenEvidence a 'probable' IPO candidate within six months on September 2, 2026, but that is an analyst assessment, not a company-confirmed date.
What is OpenEvidence worth?
Business Insider reported on September 24, 2026 that OpenEvidence raised $250 million from hospital systems and Andreessen Horowitz at a $15 billion valuation, up from the $12 billion it reached in a January 2026 round.
Why does OpenEvidence's IPO timing depend on OpenAI and Anthropic?
Crunchbase News reported on September 2, 2026 that CEO Daniel Nadler believes foundation-model companies such as OpenAI and Anthropic need to go public before application-layer companies like OpenEvidence can follow, part of why Crunchbase called an OpenEvidence IPO 'probable' within six months rather than confirmed.
Can I buy OpenEvidence shares before the IPO?
Not through a public exchange. OpenEvidence is a private company, and Segmara does not sell, broker, or arrange purchases of OpenEvidence shares.
Next step
Track private-market prices free.
If this article helped explain OpenEvidence, start with the free tracker: indicative pre-IPO marks by email. No card, no documents, no brokerage account.
Segmara is an independent research site. Segmara does not sell, broker, or arrange share purchases.